ᑭᒃᑯᑐᐃᓐᓇᓄᑦ ᑐᓴᒐᒃᓴᖅ ᒐᕙᒪᒃᑯᓐᓂ

Bivalent ᓄᕙᒡᔪᐊᕐᓇᖅ-19–ᒥ ᑲᐱᔭᐅᔪᓐᓇᖅᑎᑕᐅᔪᑦ ᐃᓚᒋᐊᖅᑕᐅᔪᑦ

ᓯᑎᐱᓇ 26, 2022
ᓄᓇᕗᓕᒫᒥᑦ 30 ᑎᑦᑕᑯᓗᐃᑦ

ᐋᓐᓂᐊᖃᕐᓇᖏᑦᑐᓕᕆᔨᒃᑯᑦ ᑐᓴᐅᒪᕐᑯᔨᔪᑦ Moderna’s bivalent mRNA ᓄᕙᒡᔪᐊᕐᓇᖅ–19 ᐋᓐᓂᐊᓕᕇᒃᑯᑎ ᐱᔪᓐᓇᖅᑎᑕᐅᔪᖅ ᐅᖓᕙᕆᐊᖅᑕᐅᓂᕐᒧᑦ.

ᐱᒋᐊᖅᑎᑕᐅᓂᐊᖅᑐᖅ ᒫᓐᓇᑲᐅᑎᒋ bivalent ᐊᓐᓂᐊᓕᕇᒃᑯᑎ ᐊᑐᐃᓐᓇᐅᔪᖅ ᐅᑯᓄᖓ:

- ᓄᓇᕗᒻᒥᐅᑕᖅ 45-ᓂᒃ ᐅᑭᐅᓕᒃ ᐅᖓᑖᓄᑦᓗ.
- ᑎᒥᒥᒍᑦ ᐊᓐᓇᐅᒪᔾᔪᑎᖃᑦᑎᐊᙱᑦᑐᑦ ᓄᓇᕗᒻᒥᐅᑦ ᐅᑭᐅᓖᑦ 12 ᐊᒻᒪᓗ ᐅᖓᑖᓂᑦ.
- ᐋᓐᓂᐊᕐᕕᖕᒥᑦ ᐃᖃᓇᐃᔭᖅᑎᓕᒫᑦ.
- ᒪᒥᔅᕕᖕᒥᑦ ᐃᖃᓇᐃᔭᖅᑏᑦ ᐊᒻᒪᓗ ᓇᔪᖅᐸᒃᑐᑦ.

ᑖᓐᓇ bivalent ᑲᐱᔭᐅᔾᔪᑕᐅᓕᖅᐸᑦ ᐊᑕᐅᑦᑎᒃᑰᖅᑕᐅᔪᓐᓇᖅᑐᖅ ᓄᕙᓗᐊᕐᓇᙱᑦᑐᒧᑦ ᑲᐱᔭᐅᔪᖃᖅᑎᓪᓗᒍ.

ᑭᖑᓂᐊᒍᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ–19 mRNA ᐋᓐᓂᐊᓕᕇᒃᑯᓯᖅ ᐊᑐᐃᓐᓇᐅᑎᑕᐅᖏᓐᓇᖅᑐᖅ ᓄᓇᕗᒻᒥᐅᓄᑦ ᐅᑭᐅᓕᖕᓄᑦ ᑕᕿᑦ ᐊᕐᕕᓂᓖᑦ ᐅᖓᑖᓂᓗ. ᓄᕙᕐᔪᐊᕐᓇᖅ-19–ᒧᑦ ᑲᐱᔭᐅᔪᒪᔪᑦ ᐃᓂᒃᓴᓕᐅᕈᓐᓇᖅᐳᑦ ᐋᓐᓂᐊᕐᕕᖏᓐᓄᑦ ᐅᕐᑯᒪᐃᓐᓂᕐᓂᐊᕐᕕᖕᒧᓪᓘᓐᓃᑦ ᐅᕐᑳᓚᓗᑎᒃ.

ᐃᖃᓗᖕᓂ, ᐅᕐᑯᒪᐃᓐᓂᕐᓂᐊᕐᕕᒃ bivalent ᑳᐳᑎᒧᑦ ᐃᓂᒃᓴᓕᐅᖅᓯᒪᔪᑐᐊᑦ ᑲᐱᔭᐅᔪᓐᓇᕐᓂᐊᖅᑐᑦ, ᓯᑎᐱᓇ 26–ᒥ ᐱᒋᐊᕐᓗᓂ, ᓇᒡᒐᔾᔭᒥ ᐅᓪᓗᑐᐃᓐᓇᒧᑦ 9:30–ᒥᑦ 11:30–ᒧᑦ ᐊᒻᒪᓗ 1:00–ᒥᑦ 4:15–ᒧᑦ.

ᐱᔪᓐᓇᖅᑎᑕᐅᔪᑦ bivalent ᐋᓐᓂᐊᓕᕇᒃᑯᑎᒧᑦ ᐃᓚᒋᐊᖅᑕᐅᓂᐊᖅᐳᑦ ᐋᓐᓂᐊᓕᕆᒃᑯᑏᑦ ᐅᓄᖅᓯᒋᐊᖅᐸᑕ. ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᓕᕇᒃᑯᑏᑦ ᐱᐅᓛᒥᑦ ᓴᐳᒻᒥᔪᓐᓇᖅᑐᑦ ᐱᔫᓐᓃᖅᐹᓪᓕᖅᑎᑦᑎᓂᕐᒧᑦ ᖃᓂᒪᖕᔪᐊᕈᑕᐅᓂᕐᒧᑦ, ᐋᓐᓂᐊᕐᕕᓕᐊᕆᐊᖃᕐᓂᕐᒧᑦ ᐊᒻᒪᓗ ᐃᓅᔪᓃᕐᓂᕐᒧᑦ.

ᐊᐱᖅᑯᑎᒃᓴᖃᕈᕕᑦ ᐋᓐᓂᐊᓕᕆᒃᑯᑎᐅᑉ ᒥᒃᓵᓄᑦ, ᐅᖁᓚᕝᕕᒋᓗᒍ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᑐᑭᓯᒋᐊᕐᕕᖓ ᐊᑭᖃᙱᑦᑐᖅ ᐅᕗᖓ 1-888-975-860 8:30–ᒥ ᐅᓪᓛᑯᑦ 5:00–ᒧᐊᕋᓱᖕᓂᖓᓄᑦ. ᑲᓇᖕᓇᐅᑉ ᖃᐅᔨᓴᐅᑎᖓ ᒪᓕᒃᓗᒍ ᓇᒡᒐᔾᔭᒥ ᐅᓪᓗᑐᐃᓐᓇᕐᒧᑦ, ᑕᑯᒋᐊᕐᓗᑎᓪᓘᓐᓃᑦ ᐅᕗᖓ https://www.gov.nu.ca/iu/aanniaqangnanngittulirijikku/information/nuvagjuarnaq-19mut-kapijauniq-0.

###

ᐱᕙᓪᓕᐊᔪᓂᒃ ᖃᐅᔨᒋᐊᕐᕕᒃᓴᖅ:

ᑖᓇᕋᐃ ᓴᒧᕕᐅᓪ
ᑐᓴᒐᒃᓴᓕᕆᔨᓄᑦ ᖃᐅᔨᒪᔨᑕᖅ
ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ
867-975-5712
dsommerville1@gov.nu.ca

ᐱᕙᓪᓕᐊᔪᑦ ᑐᓴᒐᒃᓴᙳᖅᑎᑕᐅᔪᑦ ᐱᔭᐅᔪᓐᓇᖃᑦᑕᖅᑐᑦ ᐃᓄᒃᑎᑑᖓᓗᑎᒃ, ᖃᓪᓗᓈᑐᑦ, ᐃᓄᐃᓐᓇᖅᑐᓐ ᐅᐃᕖᑐᓪᓗ ᐅᕙᙱᑦ, *www.gov.nu.ca.*
News releases are available in Inuktitut, English, Inuinnaqtun and French on *www.gov.nu.ca*.
Tuhaqtaghat ittut Inuktitut, Qablunaatitut, Inuinnaqtun Uiviititullu talvani *www.gov.nu.ca*.
Les communiqués de presse sont disponibles en inuktitut, en anglais, en inuinnaqtun et en français au *www.gov.nu.ca*.

ᑐᓴᐅᒪᑎᑦᑎᓂᖅ